ArticleGastro hep advances2022
Potassium-Competitive Acid Blocker and Proton Pump Inhibitor-Based Regimens for First-Line
Article in Gastro hep advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07040839 (Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection
Who cites it
9 citing papers in PubMed.
- Potassium-Competitive Acid Blockers for First-LineGastro hep advances · 2026Review
- Breaking barriers in the first-lineWorld journal of gastroenterology · 2025Article
- Review
- Article
- Review
- Helicobacter pylori infection.Nature reviews. Disease primers · 2023Review
- Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment ofTherapeutic advances in gastroenterology · 2023Article
- Real-world outcomes associated with vonoprazan-basedTherapeutic advances in gastroenterology · 2023Article
- Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders.Gastroenterology & hepatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Effective acid suppression is a crucial component of Methods: Studies reporting first-line Results: Twenty-three distinct regimens from 42 trials including 12,773 patients were identified. Vonoprazan-based triple therapy showed the highest relative efficacy (odds ratio: 2.73, 95% credible interval 2.11, 3.54) and 72.1% probability of being the best. North American, Western, and global scenarios were largely consistent. Vonoprazan-based therapies demonstrated higher odds of Conclusion: Vonoprazan-based eradication regimens represent novel treatments for
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.